Fizazi, et al. ARAMIS: Efficacy and safety of darolutamide in nonmetastatic castration-resistant prostate cancer (nmCRPC). ASCO-GU 2019, abstract 140.
Versnelde FDA-goedkeuring lifileucel (Amtagvi) voor melanoom
mrt 2024 | Dermato-oncologie, Immuuntherapie